Alkem’s NeuCeno brings cenobamate to Indian patients, offering a once-daily anti-seizure treatment option for adults with partial-onset seizures.
Hospital consumables could be next in line for NPPA price control as regulators examine steep markups and growing calls for structured price monitoring.
September has emerged as the worst month for dengue in Delhi this year, with the Municipal Corporation of Delhi reporting 121 cases so far.
Dr. Reddy’s Laboratories enters India’s nivolumab race with Nivorz, adding biosimilar competition to the cancer drug market.
FDA Today brings fresh developments across drug access, approvals and new pathways, spanning oncology, respiratory care and emerging psychedelic therapies.
Lymphoma and its treatment can affect immune protection, making everyday infections a greater concern. Awareness, vaccination, monitoring and support can help patients navigate daily life.
India’s proposed easier drug rules could help pharma companies shorten development timelines, accelerate generic launches, and improve access to affordable medicines.
GSK’s oncology buying spree gains momentum with a USD 750 million blood cancer bet targeting a potential new multiple myeloma treatment.
Lilly claims 30 percent share as the oral weight-loss race intensifies, challenging Novo Nordisk’s early lead in the growing obesity treatment market.
AI-backed cancer care gains international attention as India-built iOncology.ai earns recognition at BRICS while moving toward clinical validation.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")